Phase 1 B-cell Lymphoma Clinical Trials
100 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 100 trials
Recruiting
Phase 1
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto19 enrolled1 locationNCT05963217
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1Phase 2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 1
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting
Phase 1Phase 2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled21 locationsNCT04989803
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 1
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center33 enrolled1 locationNCT05773040
Recruiting
Phase 1
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 1Phase 2
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Burkitt LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsDouble-Expressor Lymphoma
National Cancer Institute (NCI)50 enrolled4 locationsNCT07069699
Recruiting
Phase 1
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Large B-cell Lymphoma
Washington University School of Medicine24 enrolled1 locationNCT07052305
Recruiting
Phase 1Phase 2
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaB-cell Lymphoma
Shenzhen University General Hospital10 enrolled1 locationNCT07584889
Recruiting
Phase 1
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167